Novartis Pharmaceuticals Canada Inc. (Novartis) is pleased to announce that, as of July 2, 2025, Pluvicto® (lutetium (177Lu) vipivotide tetraxetan injection) is publicly reimbursed in Quebec for ...

The global Radioligand Therapy (RLT) market is poised to reach US$13 billion by 2030, expanding at a ~5% CAGR over the ...

Actinium Pharmaceuticals, Inc. (NYSE:ATNM) is among the best growth stocks to invest in for the next 5 years. During the ...

Financial giant UBS has declared that enough is enough with lagging healthcare valuations – and now believes it will be the ...

Lantheus Holdings offers a compelling bull case, with PYLARIFY and DEFINITY driving valuation and strong growth prospects.